Wound Infiltration of Liposomal Bupivacaine v Plain Bupivacaine for Post-Op Pain Control in Elective Cesarean Delivery

Recruiting in Palo Alto (17 mi)

Overseen by Brian M Fitzgerald, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Brooke Army Medical Center

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Randomized double blind placebo controlled trial to compare the post-operative pain control advantages of post-incisional wound infiltration with liposomal bupivacaine to plain bupivacaine in patients presenting for elective caesarean delivery.

Eligibility Criteria

Inclusion Criteria

ASA I or II women with uncomplicated singleton pregnancies

≥37 weeks gestation

≥18 years old presenting

Participant Groups

Group I: Plain Bupivacaine Experimental Treatment 1 Intervention

Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)

Group II: Liposomal Bupivacaine Experimental Treatment 1 Intervention

Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded

Group III: Normal Saline Placebo Group 1 Intervention

Subject will receive 20ml of normal saline infiltration

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Brooke Army Medical Center Fort Sam Houston, TX

Who Is Running the Clinical Trial?

Brooke Army Medical Center Lead Sponsor

References